Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MountainTap-5: BMS-986504 in MTAP-deleted Advanced Solid Tumors
jRCT2031260329Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of MRTX1719 in melanoma, gastric adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC) and 3 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Part 1 Objective Response, Part 2 Dose-Limiting Toxicities and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
melanomagastric adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)transitional cell carcinoma (TCC)advanced nonhematological malignancy
Beyond the preview
Go deeper on jRCT2031260329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260329.